NDAINTRAVITREALSOLUTIONPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation.
Clinical Trials (1)
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Started Jan 2025
1,000 enrolled
Geographic AtrophyMacular Degeneration
Loss of Exclusivity
LOE Date
Jul 11, 2034
101 months away
Patent Expiry
Jul 11, 2034
Company
Astellas
China - Shenyang